Moreno-Grau, Sonia
Vernekar, Manvi
Lopez-Pineda, Arturo
Mas-Montserrat, Daniel
Barrabés, Míriam
Quinto-Cortés, Consuelo D.
Moatamed, Babak
Lee, Ming Ta Michael
Yu, Zhenning
Numakura, Kensuke
Matsuda, Yuta
Wall, Jeffrey D.
Ioannidis, Alexander G.
Katsanis, Nicholas
Takano, Tomohiro
Bustamante, Carlos D.
Funding for this research was provided by:
New Energy and Industrial Technology Development Organization (JPNP19001)
Article History
Received: 15 June 2024
Accepted: 19 August 2024
First Online: 2 September 2024
Declarations
:
: This study was approved by the institutional review board (IRB) at WCG IRB () under IRB tracking number protocol number 20201332.
: AI, ALP, BM, CDB, CQC, DMM, MBT, JDW, MTML, NK, and SMG are employees of or consultants to Galatea Bio. MV, ZY, KN, YM, and TT are employees of Genomelink. CDB, IA, and NK are founders and shareholders of Galatea Bio stock. CDB, KN, YM, and TT are shareholders of Genomelink stock. The remaining authors declare that there is no conflict of interest regarding the publication of this article.